Fox Run Management L.L.C. Acquires Shares of 12,905 Altimmune, Inc. (NASDAQ:ALT)

Fox Run Management L.L.C. bought a new position in Altimmune, Inc. (NASDAQ:ALT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 12,905 shares of the company’s stock, valued at approximately $93,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. lifted its position in Altimmune by 12.9% during the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after buying an additional 2,687 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Altimmune by 19.2% in the 4th quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock worth $153,000 after acquiring an additional 3,423 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in Altimmune by 34.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock valued at $98,000 after acquiring an additional 3,500 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC purchased a new stake in Altimmune in the third quarter worth about $31,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ALT has been the topic of a number of analyst reports. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Tuesday, March 18th. Finally, William Blair restated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Trading Down 4.5 %

Altimmune stock opened at $5.32 on Friday. Altimmune, Inc. has a 12 month low of $5.14 and a 12 month high of $11.16. The stock has a fifty day simple moving average of $6.24 and a two-hundred day simple moving average of $7.06. The firm has a market cap of $409.71 million, a price-to-earnings ratio of -3.43 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, equities research analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Insider Activity

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.